GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (STU:0ET) » Definitions » Short-Term Debt

Esperion Therapeutics (STU:0ET) Short-Term Debt : €52.1 Mil (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Esperion Therapeutics Short-Term Debt?

Esperion Therapeutics's Short-Term Debt for the quarter that ended in Dec. 2024 was €52.1 Mil.

Esperion Therapeutics's quarterly Short-Term Debt stayed the same from Jun. 2024 (€0.0 Mil) to Sep. 2024 (€0.0 Mil) but then increased from Sep. 2024 (€0.0 Mil) to Dec. 2024 (€52.1 Mil).

Esperion Therapeutics's annual Short-Term Debt stayed the same from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil) but then increased from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€52.1 Mil).


Esperion Therapeutics Short-Term Debt Historical Data

The historical data trend for Esperion Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Short-Term Debt Chart

Esperion Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Short-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 52.12

Esperion Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 52.12

Esperion Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Esperion Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Headlines

No Headlines